Meeting
2021 ASCO Annual Meeting
KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.
Presenter
Conrad R. Jacobs, MD
East Cape Onc
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03665597
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9541)
DOI
10.1200/JCO.2021.39.15_suppl.9541
Abstract #
9541
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.
Speaker: Sapna Pradyuman Patel, MD
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
Speaker: Sajeve Samuel Thomas
Videos & Slides
2024 ASCO Annual Meeting
Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.
Speaker: Anthony W. Tolcher, MD, FASCO